Filing Flows › Teva Pharmaceutical Industries (TEVA) › Guidance & outlook
Teva Pharmaceutical Industries (TEVA) guidance and outlook
Teva Pharmaceutical Industries (TEVA) raised some and lowered other parts of its guidance on Nov 3, 2026: Revenue $2.5B–$2.6B for FY2026; Tax rate 20%–23% for FY2026; Operating income $100M for FY2026; Tax rate 20%–23% for FY2026. Teva Pharmaceutical Industries' 10-Q filed Nov 3, 2026 makes 8 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $2.5B–$2.6B | raised |
| Revenue | FY2026 | $1.5B–$2.0B | new |
| Tax rate | FY2026 | 20%–23% | reaffirmed |
| Operating income | FY2026 | $100M | raised |
| Tax rate | FY2026 | 20%–23% | reaffirmed |
| EPS | FY2026 | $0.07 | lowered |
From the earnings release filed Nov 3, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 3, 2026
- During this phase, we expect to focus on growing our innovative portfolio, aligning capital allocation to invest in activities we expect to have the highest value, and modernizing our organization and operations to drive both efficiency and cost savings.
- Under Teva’s Transformation Programs announced on May 7, 2025, we expect to achieve such cost savings through a variety of initiatives, including examining practices and efficiencies in methods of working, reduction in headcount and optimizing external spend in the following years.
- We are evaluating plans to launch UZEDY in other countries around the world.
- In 2024, we announced that we intend to divest our API business (including its R&D, manufacturing and commercial activities) through a sale.
- Our spending takes place throughout the development process, including (i) early-stage projects in both discovery and preclinical phases; (ii) middle-stage projects in clinical programs up to Phase 3; (iii) late-stage projects in Phase 3 programs, including where a new drug application is currently pending approval; (iv) post-approval studies for marketed products; and (v) indirect expenses, such as costs of…
- This increase was mainly due to higher expenses in our immunology and neuroscience projects, as well as in our biosimilars pipeline .
- In connection with these efforts, we have been able to secure more favorable payment terms from many of our vendors and expect to continue with these efforts in future periods.
- In addition, in periods in which collections from customers are delayed, we have and expect we may in the future extend the time to pay certain vendors, so as to balance our liquidity position.
Teva Pharmaceutical Industries' latest quarter
Teva Pharmaceutical Industries, Q3 2026: revenue $4.4B (-2% year over year), operating margin 16.2%, net earnings $234M, operating cash flow $241M. The chart follows the revenue to costs, profit and cash.
Questions
Did Teva Pharmaceutical Industries raise or lower its guidance?
Teva Pharmaceutical Industries (TEVA) raised some and lowered other parts of its guidance on Nov 3, 2026: Revenue $2.5B–$2.6B for FY2026; Tax rate 20%–23% for FY2026; Operating income $100M for FY2026; Tax rate 20%–23% for FY2026.
What does Teva Pharmaceutical Industries expect?
During this phase, we expect to focus on growing our innovative portfolio, aligning capital allocation to invest in activities we expect to have the highest value, and modernizing our organization and operations to drive both efficiency and cost savings. Under Teva’s Transformation Programs announced on May 7, 2025, we expect to achieve such cost savings through a variety of initiatives, including examining practices and efficiencies in methods of working, reduction in headcount and optimizing external spend in the following years. We are evaluating plans to launch UZEDY in other countries aro
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.